Helen E. Heslop

Houston Methodist — United States

Medicine · Health Sciences

103h-index45.0kcitations816works17.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(363), Cytomegalovirus and herpesvirus research(188), Virus-based gene therapy research(177), Immune Cell Function and Interaction(177), Viral-associated cancers and disorders(141)

Publications809 total

Statin therapy with CD19-directed CAR-T therapy improves outcomes in relapsed or refractory large B-cell lymphoma
Blood Immunology & Cellular Therapy·2025Open Access
Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial
Blood·2025Open Access
CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial
Blood·2025
Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy
Blood·2025Open Access
Provider practices and preparedness for gene therapy in pediatric sickle cell disease: A national survey of pediatric hematologists
Blood·2025Open Access
MT-601 demonstrates favorable safety and durable responses in relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL)
Blood·2025
553 A phase I clinical trial of allogeneic NKT cells expressing a CD19-specific CAR in patients with relapsed or refractory B cell malignancies: an interim analysis
Regular and Young Investigator Award Abstracts·2025Open Access
Autologous multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma (PDAC): results of a Phase I, three-arm, nonrandomized clinical trial (TACTOPS)
immuneACCESS·2025
A phase 2 study to confirm safety and efficacy of MB-105, an autologous CD5-directed CAR T-cell therapy, in relapsed/refractory T-cell lymphoma (R/R TCL).
Journal of Clinical Oncology·2025
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma
Nature Medicine·2025· 36 cited
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas
Blood Advances·2025· 2 citedOpen Access
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Carolina Digital Repository (University of North Carolina at Chapel Hill)·2024· 6 citedOpen Access
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Nature·2024· 155 citedOpen Access
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
UNC Libraries·2024· 1 citedOpen Access
Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas
Blood·2024· 2 cited
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant
Transplantation and Cellular Therapy·2024· 2 citedOpen Access
Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapy
2024Open Access
Time to optimize vaccination strategies in blood cancer patients
British Journal of Haematology·2024· 1 citedOpen Access
Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA).
Journal of Clinical Oncology·2024· 8 cited
Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies
Molecular Therapy·2024· 18 citedOpen Access
page 1 of 41Next →

Frequent Co-authors

Cliona M. Rooney(44), Malcolm K. Brenner(41), Adrian P. Gee(24), Gianpietro Dotti(20), Barbara Savoldo(18), Hao Liu(16), Robert A. Krance(14), Catherine M. Bollard(13), Bambi Grilley(12), Stephen Gottschalk(12), Carlos A. Ramos(10), Zhuyong Mei(9), Enli Liu(8), Meng-Fen Wu(8), Ann M. Leen(8), M. Helen Huls(7), Karin Straathof(6), Catherine Y. Ng(6), Martin Pulé(6), George Carrum(6)